litlas
Log inCreate account

Richard G. Langley

Active 2001–2025

Also published as
Richard G Langley
111
Papers
23,991
Citations
77
h-index
104
i10-index

Citations

Citations per year for Richard G. Langley1984: 1 citations1998: 5 citations2001: 2 citations2002: 20 citations2003: 42 citations2004: 37 citations2005: 51 citations2006: 43 citations2007: 81 citations2008: 120 citations2009: 155 citations2010: 119 citations2011: 162 citations2012: 177 citations2013: 190 citations2014: 179 citations2015: 237 citations2016: 275 citations2017: 386 citations2018: 379 citations2019: 938 citations2020: 976 citations2021: 824 citations2022: 680 citations2023: 653 citations2024: 897 citations2025: 456 citations2026: 2 citations1985–1997: no citations, so these years are not shown1999–2000: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,822 citing papers, 22.7% of this breakdownGermany: 636 citing papers, 7.9% of this breakdownUnited Kingdom: 624 citing papers, 7.8% of this breakdownCanada: 567 citing papers, 7.1% of this breakdownItaly: 499 citing papers, 6.2% of this breakdownChina: 422 citing papers, 5.3% of this breakdownFrance: 340 citing papers, 4.2% of this breakdownSwitzerland: 293 citing papers, 3.6% of this breakdownSpain: 284 citing papers, 3.5% of this breakdownJapan: 268 citing papers, 3.3% of this breakdownNetherlands: 202 citing papers, 2.5% of this breakdownDenmark: 177 citing papers, 2.2% of this breakdown
0%22.7%Other 23.7%

Institutions

Fields

  • Immunology and Microbiology53.2%
  • Medicine34.9%
  • Biochemistry, Genetics and Molecular Biology7.3%
  • Neuroscience1.6%
  • Pharmacology, Toxicology and Pharmaceutics0.8%
  • Engineering0.5%
  • Other1.7%

Topics

  • Psoriasis: Treatment and Pathogenesis21.4%
  • Dermatology and Skin Diseases12.2%
  • Spondyloarthritis Studies and Treatments9.9%
  • Rheumatoid Arthritis Research and Therapies4.1%
  • Asthma and respiratory diseases2.8%
  • Inflammatory Bowel Disease2%
  • Other47.6%

Coauthors

All papers

Open in search
  1. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

    Authors: Richard G. Langley, Boni E. Elewski, Mark Lebwohl, Kristian Reich, C.E.M. Griffiths, Kim Papp, L. Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson, Enrique Rivas, Tsen‐Fang Tsai, Norman Wasel, Stephen K. Tyring, Thomas Salko, Isabelle Hampele, Marianne Notter, Alexander Karpov, Silvia Helou, C. Papavassilis - New England Journal of Medicine 2014 cited by 1,964

  2. Bimekizumab versus Secukinumab in Plaque Psoriasis

    Authors: Kristian Reich, Richard B. Warren, Mark Lebwohl, Melinda Gooderham, Bruce Strober, Richard G. Langley, C. Paul, Dirk De Cuyper, Veerle Vanvoorden, Cynthia Madden, Christopher L. Cioffi, Luke Peterson, Andrew Blauvelt - New England Journal of Medicine 2021 cited by 400

  3. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

    Authors: Kenneth B. Gordon, Andrew Blauvelt, Kim Papp, Richard G. Langley, Thomas A. Luger, Mamitaro Ohtsuki, Kristian Reich, David A. Amato, Susan Ball, Daniel Braun, Gregory S. Cameron, J. Erickson, Robert J. Konrad, Talia M. Muram, Brian J. Nickoloff, Olawale Osuntokun, Roberta J. Secrest, Fangyi Zhao, Lotus Mallbris, Craig L. Leonardi - New England Journal of Medicine 2016 cited by 838

  4. Psoriasis: epidemiology, clinical features, and quality of life

    Authors: Richard G. Langley, G G Krueger, C E M Griffiths - Annals of the Rheumatic Diseases 2005 cited by 1,107

  5. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

    Authors: Kristian Reich, April W. Armstrong, Richard G. Langley, Susan Flavin, B. Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt - The Lancet 2019 cited by 376

  6. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

    Authors: Kristian Reich, Kim Papp, Andrew Blauvelt, Richard G. Langley, April W. Armstrong, Richard B. Warren, Kenneth B. Gordon, Joseph F. Merola, Yukari Okubo, Cynthia Madden, Maggie Haitian Wang, Christopher L. Cioffi, Veerle Vanvoorden, Mark Lebwohl - The Lancet 2021 cited by 297

  7. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    Authors: Kim Papp, Kristian Reich, Craig L. Leonardi, Leon Kircik, Sergio Chimenti, Richard G. Langley, ChiaChi Hu, Randall M. Stevens, Robert M. Day, Kenneth B. Gordon, Neil J. Korman, C.E.M. Griffiths - Journal of the American Academy of Dermatology 2015 cited by 669

  8. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

    Authors: Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth B. Gordon, Jolanta Węgłowska, L. Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco A. Kerdel, April W. Armstrong, Georg Stingl, Alexa B. Kimball, H. Bachelez, Jashin J. Wu, Jeffrey Crowley, Richard G. Langley, Tomasz Blicharski, C. Paul, J.‐P. Lacour, Stephen K. Tyring, Leon Kircik, Sergio Chimenti, Kristina Callis Duffin, Jerry Bagel, John Koo, Gary Aras, Joanne Li, Wenjie Song, Cassandra E. Milmont, Yifei Shi, Ngozi Erondu, Paul Klekotka, Brian L. Kotzin, Ajay Nirula - New England Journal of Medicine 2015 cited by 806

  9. Bimekizumab versus Adalimumab in Plaque Psoriasis

    Authors: Richard B. Warren, Andrew Blauvelt, Jerry Bagel, Kim Papp, Paul S. Yamauchi, April W. Armstrong, Richard G. Langley, Veerle Vanvoorden, Dirk De Cuyper, Christopher L. Cioffi, Luke Peterson, Nancy Cross, Kristian Reich - New England Journal of Medicine 2021 cited by 238

  10. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

    Authors: Kim Papp, Richard G. Langley, Mark Lebwohl, Gerald G. Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li, Lisa T. Dooley, Kristian Reich - The Lancet 2008 cited by 1,350

  11. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial

    Authors: Richard G. Langley, Tsen‐Fang Tsai, Susan Flavin, Michael Song, B. Randazzo, Yasmine Wasfi, Jingzhi Jiang, S. Li, L. Puig - British Journal of Dermatology 2017 cited by 339

  12. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

    Authors: Kim Papp, Alan Menter, Mai Abe, Boni E. Elewski, Steven R. Feldman, Alice B. Gottlieb, Richard G. Langley, Thomas A. Luger, Diamant Thaçi, M. Buonanno, Pankaj Gupta, James Proulx, Shu-Ping Lan, Robert Wołk, the OPT Pivotal 1 and OPT Pivotal 2 investigators - British Journal of Dermatology 2015 cited by 322

  13. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

    Authors: Andrew Blauvelt, Craig L. Leonardi, Melinda Gooderham, Kim Papp, Sandra Philipp, Jashin J. Wu, Atsuyuki Igarashi, Mary Flack, Ziqian Geng, Tianshuang Wu, Anne Camez, David Williams, Richard G. Langley - JAMA Dermatology 2020 cited by 216

  14. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial

    Authors: Andrew Blauvelt, Richard G. Langley, J.‐P. Lacour, Darryl Toth, Vivian Laquer, Stefan Beissert, Andreas Wollenberg, Pedro Herranz, Andrew Pink, Ketty Peris, Stine Fangel, Le Gjerum, Joshua Corriveau, Hidehisa Saeki, Richard B. Warren, Eric L. Simpson, Kristian Reich - Journal of the American Academy of Dermatology 2022 cited by 75

  15. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

    Authors: Kim Papp, Kristian Reich, C. Paul, Andrew Blauvelt, Wojciech Baran, Chantal Bolduc, D. Toth, Richard G. Langley, Jennifer Clay Cather, Alice B. Gottlieb, Diamant Thaçi, James G. Krueger, Chris B. Russell, C.E. Milmont, Jing Li, Paul Klekotka, Greg Kricorian, Ajay Nirula - British Journal of Dermatology 2016 cited by 459

  16. Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities

    Authors: Alan Menter, Gerald G. Krueger, So Yeon Paek, Darío Kivelevitch, Iannis E. Adamopoulos, Richard G. Langley - Dermatology and Therapy 2021 cited by 108

  17. Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis*

    Authors: Kenneth B. Gordon, Mark Lebwohl, Kim Papp, H. Bachelez, Jashin J. Wu, Richard G. Langley, Andrew Blauvelt, Beth Kaplan, Megha Shah, Yiwei Zhao, Ranjeeta Sinvhal, Kristian Reich - British Journal of Dermatology 2021 cited by 99

  18. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

    Authors: Andrew Blauvelt, Kim Papp, Alice B. Gottlieb, Abel Jarell, Kristian Reich, Catherine Maari, Kenneth B. Gordon, Laura K. Ferris, Richard G. Langley, Yayoi Tada, Renata Gontijo Lima, Hany Elmaraghy, Gaia Gallo, L. Renda, S‐M. Park, Russel Burge, Jerry Bagel, the IXORA‐R Study Group, Ronald Vender, Mark Lomaga, Isabelle Delorme, Chih-ho Hong, Richard L. Langley, Lorne Albrecht, Lyn Guenther, Catherine Maari, Kim Papp, Kamal Ohson, Kirk Barber, Charles Lynde, Aditya Gupta, Leslie Rosoph, Jean‐Sébastien Gauthier, Melinda Gooderham, Norman Wasel, Mani Raman, Marni Wiseman, David Greenstein, Abel Jarell, C. A. L. Moon, Lani Clark, S. Jazayeri, Michael Bukhalo, Angela Moore, Tiffani K. Hamilton, Aron Gewirtzman, Lydie Hazan, Jeffrey Crowley, Craig Teller, Matthew Zirwas, Stacy Smith, Mark Lee, Stephen K. Tyring, Patricia Lee, Sunil Dhawan, Craig L. Leonardi, Amarilis Perez‐De Jesus, Wendy McFalda, Ellen Frankel, Paul S. Yamauchi, Scott Fretzin, Rocco Serrao, Todd Schlesinger, Scott Gottlieb, Peter Jenkin, Rola Gharib, Steven A. Davis, Navid Nami, Zoe Diana Draelos, Lloyd Godwin, Cindy E. Owen, Megan N. Landis, William Abramovits, Samuel Sanchez‐Rivera, Abby Van Voorhees, David Fivenson, Francisco A. Kerdel, Seth Forman, Jeffrey S. Weinberg, José González-Chávez, Brent Boyce, Linda Stein‐Gold, Charles P. Hudson, Constance Brown, James Coggi, Christina Feser, Rion Forconi, Sandra Johnson, Mark McCune, Lawrence Green, Vandana Madkan, Dana Maxwell Shipp, Kenneth B. Gordon, Jill Waibel, Oscar Soto‐Raices, Jennifer Cather, Scott Miller, John P. Scott, Douglas Young, Jessica Kaffenberger and 42 more - British Journal of Dermatology 2019 cited by 172

  19. The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials

    Authors: Richard G. Langley, Steven R. Feldman, Judit Nyirady, Peter van de Kerkhof, C. Papavassilis - Journal of Dermatological Treatment 2013 cited by 261

  20. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study

    Authors: Kim Papp, Alan Menter, Bruce Strober, Richard G. Langley, M. Buonanno, Robert Wołk, Pankaj Gupta, S. Krishnaswami, Huaming Tan, Jane Harness - British Journal of Dermatology 2012 cited by 336

  21. Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

    Authors: Mark Lebwohl, H. Bachelez, Jonathan Barker, Giampiero Girolomoni, Arthur Kavanaugh, Richard G. Langley, C. Paul, L. Puig, Kristian Reich, P.C.M. van de Kerkhof - Journal of the American Academy of Dermatology 2014 cited by 511

  22. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

    Authors: Alan Menter, Stephen K. Tyring, Kenneth B. Gordon, Alexa B. Kimball, Craig L. Leonardi, Richard G. Langley, Bruce Strober, Martin Kaul, Yihua Gu, Martin M. Okun, Kim Papp - Journal of the American Academy of Dermatology 2007 cited by 883

  23. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

    Authors: Richard G. Langley, Steven R. Feldman, Chenglong Han, Brad Schenkel, Philippe Szapary, Ming-Chun Hsu, Jean-Paul Ortonne, Kenneth B. Gordon, Alexa B. Kimball - Journal of the American Academy of Dermatology 2010 cited by 216

  24. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*

    Authors: Andrew Blauvelt, C. Leonardi, Boni E. Elewski, Jeffrey Crowley, Lyn Guenther, Melinda Gooderham, Richard G. Langley, Ronald Vender, Andreas Pinter, C.E.M. Griffiths, Yayoi Tada, Hany Elmaraghy, Renata Gontijo Lima, Gaia Gallo, L. Renda, Russel Burge, S.Y. Park, Baojin Zhu, Kim Papp, the IXORA‐R Study Group - British Journal of Dermatology 2020 cited by 117